Komori
Results4893Noile-Immune Biotech Inc.Pharmaceuticals

Financial Results for the Third Quarter of the Fiscal Year Ending December 2026 [Japanese GAAP] (Non-consolidated)

Cumulative business revenue for the third quarter fell to zero from ¥5 million in the same period of the previous year, while the operating loss widened slightly. Meanwhile, the ordinary loss and quarterly net loss narrowed from the same period of the previous year, due to subsidy income and other factors.

Worth reading
33Immaterial
0–100. This measures how worthwhile something is to read, not how good or bad the company is.
Direction
Mixed performance
Direction inferred from the company’s description.
Scale
612.572
¥ millions (operating loss)
Wording
Conditional
How definitive the wording is.

Results for this period

Third quarter1 January 2026–30 September 2026Non-consolidated (individual)Japanese GAAP
Operating profit612¥ million
Ordinary income557¥ million
Net income attributable to owners of the parent559¥ million

The width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit.

Net income per share-¥12.91
Financial position at period-end
Total assets3,448¥ million
of which net assets 3,387 ¥ millionEquity ratio 98.0%vs. prior year-end +0.2pt

塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.

Outlook and shareholder returns
Annual Dividend Forecast¥0.00 → ¥0.00(0%)
Factors Behind Changes in Business Performance

Although no business revenue was recorded, the continued development resulted in an operating loss.

Disclosure regarding the going concern assumption

None

Change in accounting policy
基準改正に伴う変更 Noneそれ以外の変更 None見積りの変更 None修正再表示 None
Material subsequent eventsThe 14th series of stock acquisition rights issued through a third-party allotment was issued on 5 October 2026 and partially exercised from 6 October 2026 onward. A total of 1,410,000 common shares were issued, and the total exercise price was ¥125.820 million.
Depreciation and amortization¥0 thousand
Availability of Supplementary Financial Results MaterialsNone
Availability of Financial Results BriefingNo (対象者:not applicable)
Issued Shares at Period-End43,399,118 shares
Treasury Shares at Period-End125 shares
Results for this period
ItemDetails
Fiscal Period ClassificationThird quarter
Accounting standardsJapanese GAAP
Consolidated / non-consolidatedNon-consolidated (individual)
Period Covered1 January 2026–30 September 2026
Operating profit△612
Ordinary income△557
Profit attributable to owners of the parent△559
Net income per share-¥12.91
Equity ratioEnd of the current fiscal period 98.0% / End of previous period 97.8%
Total assets¥3,448 million
Net assets¥3,387 million
Annual Dividend Forecast¥0.00 → ¥0.00(0%)
Depreciation and amortization¥0 thousand
Disclosure regarding the going concern assumptionNone
Change in accounting policyChanges due to revisions to standards None / Other changes None / Change in accounting estimate None / Restatement None
Material subsequent eventsThe 14th series of stock acquisition rights issued through a third-party allotment was issued on 5 October 2026 and partially exercised from 6 October 2026 onward. A total of 1,410,000 common shares were issued, and the total exercise price was ¥125.820 million.
Availability of Supplementary Financial Results MaterialsNone
Availability of Financial Results BriefingNo (対象者:not applicable)
Issued Shares at Period-End43,399,118 shares
Treasury Shares at Period-End125 shares
Factors Behind Changes in Business PerformanceAlthough no business revenue was recorded, the continued development resulted in an operating loss.
Items this document does not state (17)
Net SalesOperating MarginCash flows from operating activitiesCash flows from investing activitiesCash flows from financing activitiesCash and cash equivalents at end of periodFull-year earnings forecastRevision to Earnings ForecastPayout ratioShareholder Return PolicySegment revenueSegment profitRegional salesOrders received and order backlogImpairment lossBreakdown of extraordinary income (loss)Changes in the scope of consolidation

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

The company explained that, although no business revenue was recorded, the continued development resulted in an operating loss.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Financial Results for the Third Quarter of the Fiscal Year Ending December 2026 [Japanese GAAP] (Non-consolidated) | Noile-Immune Biotech Inc. (4893) timely disclosure | Komori